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Abstract 
Background: The global prevalence of type 2 diabetes‑related complications is not well described. We assessed 
prevalence of vascular complications at baseline in DISCOVER (NCT02322762; NCT02226822), a global, prospective, 
observational study program of 15,992 patients with type 2 diabetes initiating second‑line therapy, conducted across 
38 countries.
Methods: Patients were recruited from primary and specialist healthcare settings. Data were collected using a stand‑
ardized case report form. Prevalence estimates of microvascular and macrovascular complications at baseline were 
assessed overall and by country and region, and were standardized for age and sex. Modified Poisson regression was 
used to assess factors associated with the prevalence of complications.
Results: The median duration of type 2 diabetes was 4.1 years (interquartile range [IQR]: 1.9–7.9 years), and the 
median glycated hemoglobin  (HbA1c) level was 8.0% (IQR: 7.2–9.1%). The crude prevalences of microvascular and 
macrovascular complications were 18.8% and 12.7%, respectively. Common microvascular complications were periph‑
eral neuropathy (7.7%), chronic kidney disease (5.0%), and albuminuria (4.3%). Common macrovascular complications 
were coronary artery disease (8.2%), heart failure (3.3%) and stroke (2.2%). The age‑ and sex‑standardized prevalence 
of microvascular complications was 17.9% (95% confidence interval [CI] 17.3–18.6%), ranging from 14.2% in the 
Americas to 20.4% in Europe. The age‑ and sex‑standardized prevalence of macrovascular complications was 9.2% 
(95% CI 8.7–9.7%), ranging from 4.1% in South‑East Asia to 18.8% in Europe. Factors positively associated with vascular 
complications included age (per 10‑year increment), male sex, diabetes duration (per 1‑year increment), and history 
of hypoglycemia, with rate ratios (95% CIs) for microvascular complications of 1.14 (1.09–1.19), 1.30 (1.20–1.42), 1.03 
(1.02–1.04) and 1.45 (1.25–1.69), respectively, and for macrovascular complications of 1.41 (1.34–1.48), 1.29 (1.16–1.45), 
1.02 (1.01–1.02) and 1.24 (1.04–1.48), respectively.  HbA1c levels (per 1.0% increment) were positively associated with 
microvascular (1.05 [1.02–1.08]) but not macrovascular (1.00 [0.97–1.04]) complications.
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Background
Type 2 diabetes is associated with disabling and poten-
tially life-threatening microvascular and macrovascular 
complications [1, 2]. As many as 80% of patients with 
type 2 diabetes develop cardiovascular complications, 
which account for approximately 65% of deaths in this 
group [3–5]. The contribution of microvascular compli-
cations to type 2 diabetes morbidity is also substantial 
[2, 6]. Large prospective studies have demonstrated that 
intensive glycemic control decreases the incidence and 
delays the progression of microvascular complications 
in patients with type 2 diabetes [7–12]. The benefits of 
intensive glycemic control in reducing the incidence of 
macrovascular complications are less clear; however, 
previous studies have demonstrated that better glycemic 
control may modestly reduce the long-term risk of some 
macrovascular events. Furthermore, recent cardiovascu-
lar outcome trials [13, 14] and a large observational study 
[15] have suggested that some glucose-lowering agents 
may substantially improve cardiovascular outcomes in 
patients with type 2 diabetes.
Previous estimates from observational studies of the 
prevalence of vascular complications in patients with 
type 2 diabetes vary greatly [16–21], and a lack of stand-
ardization in the assessment methods used renders them 
difficult to compare. Better understanding of the burden 
of vascular complications in patients with type 2 diabetes 
across the globe is of considerable importance, particu-
larly in countries where no data are currently available, 
because this will provide critically important information 
for decisions on health policy, including strategies for 
complication prevention.
There is a paucity in particular regarding global, com-
parative data on baseline characteristics, treatment path-
ways and outcomes in patients with type 2 diabetes who 
are relatively early in the disease process at the time of 
initiating second-line glucose-lowering therapy. It is par-
ticularly important to obtain comparative data, given the 
plethora of second-line treatment options for patients 
with type 2 diabetes, compared with the first-line setting 
in which metformin monotherapy is well established and 
recommended by major treatment guidelines. To address 
this important knowledge gap, we initiated DISCOVER 
(NCT02322762, NCT02226822), a 3-year, prospective, 
observational study program of patients with type 2 
diabetes initiating second-line therapy, conducted in 38 
countries across six continents [22, 23]. Here, we report 
the baseline data from DISCOVER to describe the prev-
alence of vascular complications in patients with type 2 
diabetes across multiple countries and regions, using 
standardized methodology.
Methods
The methods for the DISCOVER study have been 
reported in detail elsewhere [22, 23] and are briefly sum-
marized below.
Study design
The DISCOVER program is a noninterventional, 3-year, 
prospective observational study program conducted 
across 38 countries and comprising two similar studies: 
DISCOVER in 37 countries (NCT02322762) and J-DIS-
COVER in Japan (NCT02226822). The study protocol 
was approved by the appropriate clinical research ethics 
committees in each participating country and the rele-
vant institutional review boards at each site. The protocol 
complies with the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation of Good Clinical 
Practice, and the local regulations for clinical research.
Countries and regional definition
The countries included in the study were separated into 
regions according to World Health Organization clas-
sification [24]: Africa (Algeria and South Africa); the 
Americas (Argentina, Brazil, Canada, Colombia, Costa 
Rica, Mexico, and Panama); South-East Asia (India and 
Indonesia); Europe (Austria, Czech Republic, Denmark, 
France, Italy, Netherlands, Norway, Poland, Russia, Spain, 
Sweden, and Turkey); the Eastern Mediterranean region 
(Bahrain, Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi 
Arabia, Tunisia, and United Arab Emirates); and the 
Western Pacific region (Australia, China, Japan, Malay-
sia, South Korea, and Taiwan).
Conclusions: The global burden of microvascular and macrovascular complications is substantial in these patients 
with type 2 diabetes who are relatively early in the disease process. These findings highlight an opportunity for 
aggressive early risk factor modification, particularly in regions with a high prevalence of complications.
Trial registration ClinicalTrials.gov; NCT02322762. Registered 23 December 2014. https ://clini caltr ials.gov/ct2/show/
NCT02 32276 2. ClinicalTrials.gov; NCT02226822. Registered 27 August 2014. https ://clini caltr ials.gov/ct2/show/NCT02 
22682 2
Keywords: Type 2 diabetes, Vascular complications, Observational study
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Site and investigator selection
National coordinating investigators of participating 
countries provided information on the management of 
patients with type 2 diabetes in their country, includ-
ing types of physicians (primary care practitioners, dia-
betologists, endocrinologists, cardiologists, and other 
specialists), types of practices (primary care centers 
and different types of hospital), locations of practices 
(urban or rural), and geographical distribution within 
each country. Information from the national coordinat-
ing investigators and data from literature searches were 
reviewed to establish a list of sites that would be as repre-
sentative as possible of the management of patients with 
type 2 diabetes in each country. Sites were then invited to 
participate, and those that accepted were included in the 
study.
Patient enrollment
All inclusion and exclusion criteria are shown in Addi-
tional file  1: Table  S1. Eligible patients with type 2 dia-
betes initiating a second-line glucose-lowering treatment 
(add-on or switching) after a first-line oral monotherapy 
or combination therapy were invited to participate in 
the study by their physician. Patients using an injectable 
agent (i.e. insulin or a glucagon-like peptide-1 receptor 
agonist) as first-line therapy were excluded because they 
may have had a more severe disease profile that would 
warrant a separate study. All participating patients pro-
vided signed informed consent.
Data collection
Baseline data were collected at initiation of second-line 
therapy. In most countries, the investigators collected 
data using a standardized electronic case report form, 
and data were transferred to a central database via a web-
based data capture system. In the process of data clean-
ing and preparation for analyses, data were checked for 
internal consistency and outliers (impossible values) were 
identified. Variables recorded at baseline included: demo-
graphic and socioeconomic characteristics, physiological 
parameters (blood pressure, pulse rate, weight, height, 
body mass index [BMI] and waist circumference), change 
in glucose-lowering therapy and reason(s) for change, 
glycated hemoglobin  (HbA1c) level and other labora-
tory parameters (blood test and urine test results [22]), 
occurrence of major and minor hypoglycemic events, 
comorbidities (including microvascular and macrovascu-
lar complications), comedications, and patient-reported 
outcomes. Duration of diabetes was assessed as time 
since diagnosis. In line with the observational nature of 
the study, information with regard to glycemic control 
and other clinical variables was collected as measured 
in routine clinical practice at each site, according to the 
local standard of care. Similarly, the study protocol did 
not mandate the screening for or adjudication of compli-
cation occurrence.
Vascular complications
Investigators collected information on patients’ history 
of complications or related procedures from medical 
records. Patients who had experienced either micro- or 
macrovascular disease prior to their diabetes diagnosis 
were not excluded. Diagnosis and classification of com-
plications relied on the judgment of investigators. The 
following vascular complications were assessed:
• microvascular: nephropathy (presence of chronic 
kidney disease and/or albuminuria), retinopathy (his-
tory of retinopathy or retinal laser photocoagulation), 
and neuropathy (autonomic neuropathy, peripheral 
neuropathy, and erectile dysfunction)
• macrovascular: coronary artery disease (history of 
coronary artery disease, angina, myocardial infarc-
tion, percutaneous coronary intervention, and coro-
nary artery bypass grafting), cerebrovascular disease 
(stroke, transient ischemic attack, carotid artery 
stenting, and carotid endarterectomy), peripheral 
artery disease (history of peripheral artery disease 
including revascularization procedures, diabetic foot, 
and amputation), heart failure, and implantable car-
dioverter defibrillator use.
Statistical analysis
The minimum sample size was estimated to be 11,100 
[22]. This sample size was based on the intention to have 
at least 200 patients comprising any given group or meet-
ing any of the pre-specified endpoints to be analyzed, and 
an estimated attrition rate of 15% per year of follow-up, 
as described in detail elsewhere [22]. Descriptive data 
are presented as numbers (percentages), means (stand-
ard deviations [SD]), and medians (interquartile ranges 
[IQR]), as appropriate. The crude prevalence of micro-
vascular and macrovascular complications is reported 
overall, and by country and region. In order to correct for 
geographical variations, regional and country-level prev-
alence estimates were also standardized for age and sex 
using a logistic regression model.
Factors associated with complications were assessed 
using a modified Poisson model with cluster-based sand-
wich variance estimator [25], to account for patient clus-
tering within countries. The following variables were 
included in the model, based on a literature review and 
clinical judgment: age, sex, education level, smoking 
status, BMI, systolic blood pressure (SBP),  HbA1c, total 
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cholesterol, duration of diabetes, history of hypoglyce-
mia (minor event in the previous month or major event 
in the previous year), and use of angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin receptor block-
ers (ARBs), diuretics, β-blockers, statins, and acetylsali-
cylic acid (ASA). Data were reported in > 90% of patients 
for all of these variables except  HbA1c (not reported in 
20.1% of patients) and total cholesterol (not reported 
in 42.3% of patients). To account for unreported data, 
the multiple imputation method was used for missing 
values. A comparison of the characteristics of patients 
with reported data for all variables included in the modi-
fied Poisson model, and patients with unreported data 
for either  HbA1c or total cholesterol, is shown in Addi-
tional file  1: Table  S2. The following sensitivity analyses 
were conducted: (1) an analysis including only patients 
with complete data; and (2) an analysis with additional 
variables for site specialty and patient-reported ethnic-
ity (ethnicity and specialty information was not collected 
in Canada, and specialty was not collected in France; 
these two countries were thus excluded from this analy-
sis). Rate ratios for the associations between complica-
tion prevalence and SBP, total cholesterol levels, and 
comedication use were not reported owing to reverse-
causality (we hypothesized that patients with diabetes 
complications often have high SBP and cholesterol lev-
els and receive comedications, rather than these factors 
causing vascular complications), although these factors 
were adjusted for in the model.
Imputation was carried out using IVEware (Univer-
sity of Michigan, MI, USA). All other statistical analyses 
were carried out using the SAS statistical software system 
(SAS Institute, Inc., Cary, NC, USA).
Results
Baseline patient characteristics
The overall population included 15,992 patients. Baseline 
characteristics are presented in Table  1. In total, 54.2% 
of patients were male; 49.7% were Asian, and 25.6% were 
Caucasian. The mean age was 57.2 years (SD, 12.0 years), 
ranging from 53.1 years in South-East Asia to 61.9 years 
in Europe. The median duration of diabetes was 4.1 years 
(IQR across countries: 1.9–7.9  years), varying across 
regions from 3.4 years in South-East Asia and the West-
ern Pacific region to 5.7  years in Africa. The median 
 HbA1c level at baseline was 8.0% (IQR across countries: 
7.2–9.1%) and varied across regions from 7.6% in the 
Western Pacific to 8.3% in South-East Asia and the East-
ern Mediterranean region. The mean BMI was 29.1  kg/
m2 (SD, 5.9 kg/m2) and was lowest in the Western Pacific 
region (26.1 kg/m2) and highest in Europe (31.9 kg/m2).
The most common first-line therapy was metformin 
monotherapy, both overall (56.8%) and across all regions 
(range 42.5–83.6%). The second most commonly pre-
scribed first-line therapy was sulfonylurea monotherapy 
in the Americas (6.8%), dipeptidyl peptidase-4 inhibitor 
monotherapy in the Western Pacific region (25.0%), and 
combinations of metformin and a sulfonylurea in other 
regions (range 8.3–31.1%).
Prevalence of microvascular complications
The crude prevalence of microvascular complications 
was 18.8% overall; it was greatest in Europe (23.5%) and 
lowest in Africa (14.5%; Table  2). Crude country-level 
prevalence estimates are shown in Additional file  1: 
Table  S3. The crude prevalence was 7.7% for peripheral 
neuropathy, 5.0% for chronic kidney disease, 4.3% for 
albuminuria, 3.9% for retinopathy, 2.7% for erectile dys-
function, 1.0% for autonomic neuropathy and 0.6% for 
retinal laser photocoagulation (Table 2). Peripheral neu-
ropathy was the most prevalent microvascular disease 
diagnosis in all regions except the Western Pacific (the 
most prevalent microvascular disease in the Western 
Pacific was chronic kidney disease). After standardization 
for age and sex, the prevalence of microvascular compli-
cations was 17.9% (95% confidence interval [CI] 17.3–
18.6%) overall; it remained highest in Europe (20.4% [95% 
CI 19.0–22.0%]) and was lowest in the Americas (14.2% 
[95% CI 12.7–16.0%]), ranging across countries from 2.0 
to 40.9% (Fig. 1a). Within Europe, the age- and sex-stand-
ardized prevalence of microvascular complications was 
37.3% in Russia and ranged from 4.8 to 23.0% in the other 
countries in the region. When excluding Russia from the 
analysis, the prevalence in Europe was 16.9%.
Prevalence of macrovascular complications
The crude prevalence of macrovascular complications 
was 12.7% overall and was greatest in Europe (26.7%) and 
lowest in South-East Asia (4.0%; Table 2). Crude country-
level prevalence estimates are shown in Additional file 1: 
Table  S3. The crude prevalence was 8.2% for coronary 
artery disease, 3.3% for heart failure, 2.2% for stroke, 1.2% 
for peripheral artery disease, 0.7% for transient ischemic 
attack, and 0.1% each for carotid artery stent, carotid 
endarterectomy, and defibrillator use (Table  2). After 
standardization for age and sex, the prevalence of mac-
rovascular complications was 9.2% (95% CI 8.7–9.7%) 
overall; it remained greatest in Europe (18.8% [95% CI 
17.4–20.3%]) and lowest in South-East Asia (4.1% [95% 
CI 3.5–4.9%]), ranging across countries from 3.2 to 41.6% 
(Fig.  1b). When excluding Russia from the analysis, the 
age- and sex-standardized prevalence of macrovascular 
complications in Europe was 13.7% and remained the 
highest across the regions.
The most prevalent macrovascular complication in all 
regions was coronary artery disease (2.7–18.1% across 
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Table 1 Patient demographics and baseline characteristics, overall and according to region
Total  
(N = 15,992)
Africa  
(n = 812)
Americas 
(n = 2002)
South-
East Asia 
(n = 3360)
Europe 
(n = 3479)
Eastern 
Mediterranean 
(n = 2182)
Western 
Pacific 
(n = 4157)
Proportion of 
overall popula‑
tion (%)
100.0 5.1 12.5 21.0 21.8 13.6 26.0
Sex, male, n (%) 8664 (54.2) 306 (37.7) 963 (48.1) 1852 (55.1) 1856 (53.4) 1278 (58.6) 2409 (58.0)
Age, years, mean 
(SD)
57.2 (12.0) 54.9 (11.2) 58.3 (11.8) 53.1 (11.3) 61.9 (10.9) 53.8 (10.8) 58.5 (12.6)
Self‑reported ethnicity, n (%)
 Caucasian 3917 (25.6) 105 (12.9) 480 (29.4) 1 (0.0) 3020 (94.8) 165 (7.6) 146 (3.5)
 Black 310 (2.0) 235 (29.0) 61 (3.7) 0 (0.0) 13 (0.4) 0 (0.0) 1 (0.0)
 Mixed 213 (1.4) 91 (11.2) 115 (7.0) 0 (0.0) 4 (0.1) 0 (0.0) 3 (0.1)
 Asian 7610 (49.7) 177 (21.8) 9 (0.6) 3339 (99.5) 20 (0.6) 72 (3.3) 3993 (96.1)
 Hispanic 942 (6.2) 1 (0.1) 928 (56.8) 0 (0.0) 11 (0.3) 0 (0.0) 2 (0.0)
 Arabic 2151 (14.0) 200 (24.7) 4 (0.2) 2 (0.1) 12 (0.4) 1933 (88.9) 0 (0.0)
 Other 174 (1.1) 2 (0.2) 36 (2.2) 15 (0.4) 104 (3.3) 5 (0.2) 12 (0.3)
If Asian
 Chinese 1604 (21.1) 0 (0.0) 1 (11.1) 52 (1.6) 2 (10.5) 0 (0.0) 1549 (38.8)
 South Asian 2602 (34.2) 60 (33.9) 2 (22.2) 2406 (72.1) 9 (47.4) 46 (63.9) 79 (2.0)
 East Asian 433 (5.7) 22 (12.4) 1 (11.1) 48 (1.4) 5 (26.3) 16 (22.2) 341 (8.5)
 Other Asian 2971 (39.0) 95 (53.7) 5 (55.6) 833 (24.9) 3 (15.8) 10 (13.9) 2025 (50.7)
Time in formal education, n (%)
 No formal educa‑
tion
471 (3.2) 57 (7.3) 50 (3.2) 26 (0.8) 78 (2.5) 158 (7.7) 102 (2.7)
 Primary 
(1–6 years)
2295 (15.8) 183 (23.3) 442 (28.7) 343 (10.4) 588 (19.1) 360 (17.6) 379 (10.0)
 Secondary 
(7–13 years)
7190 (49.4) 420 (53.5) 587 (38.1) 1431 (43.2) 1781 (58.0) 767 (37.5) 2204 (58.0)
 Higher 
(> 13 years)
4599 (31.6) 125 (15.9) 463 (30.0) 1514 (45.7) 626 (20.4) 759 (37.1) 1112 (29.3)
Diabetes duration since diagnosis, years
 Mean (SD) 5.6 (5.3) 6.9 (5.7) 6.2 (6.1) 4.6 (4.1) 6.6 (5.4) 5.8 (5.1) 5.1 (5.4)
 Median (IQR) 4.1 (1.9–7.9) 5.7 (2.9–9.3) 4.4 (1.9–8.7) 3.4 (2.0–6.1) 5.4 (2.7–9.1) 4.2 (2.1–8.0) 3.4 (1.0–7.6)
HbA1c (%)
 Mean (SD) 8.3 (1.7) 8.6 (1.9) 8.5 (1.9) 8.6 (1.7) 8.1 (1.6) 8.7 (1.6) 8.1 (1.7)
 Median (IQR) 8.0 (7.2–9.1) 8.0 (7.4–9.4) 8.0 (7.2–9.4) 8.3 (7.5–9.6) 7.8 (7.2–8.7) 8.3 (7.6–9.4) 7.6 (7.0–8.7)
BMI, kg/m2, mean 
(SD)
29.1 (5.9) 30.6 (6.2) 30.6 (6.1) 27.3 (4.5) 31.9 (6.1) 31.1 (5.7) 26.1 (5.0)
Tobacco smoking, n (%)
 Nonsmoker 10,831 (69.4) 633 (78.9) 1299 (66.1) 3066 (91.7) 2001 (59.9) 1579 (74.0) 2253 (56.1)
 Ex‑smoker 2537 (16.3) 93 (11.6) 460 (23.4) 128 (3.8) 791 (23.7) 189 (8.9) 876 (21.8)
 Current smoker 2232 (14.3) 76 (9.5) 205 (10.4) 151 (4.5) 546 (16.4) 366 (17.2) 888 (22.1)
SBP, mmHg, mean 
(SD)
132.3 (16.5) 134.2 (18.6) 131.2 (17.7) 128.8 (15.2) 136.4 (16.6) 133.3 (15.7) 131.6 (16.0)
DBP, mmHg, mean 
(SD)
79.9 (10.0) 80.1 (10.5) 80.6 (10.6) 79.9 (8.4) 81.1 (9.6) 79.8 (9.7) 78.6 (10.9)
TC, mg/dl, mean 
(SD)
187.0 (47.1) 179.1 (41.1) 182.1 (46.1) 179.8 (48.7) 190.6 (49.9) 189.6 (47.8) 189.6 (43.7)
History of 
 hypoglycemiaa, 
n (%)
700 (4.6) 50 (6.4) 60 (3.8) 96 (2.9) 141 (4.2) 155 (7.8) 198 (4.9)
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regions; 8.2% overall), with myocardial infarction most 
reported in Africa, the Americas, and Europe (4.0–6.6%), 
and percutaneous coronary intervention most reported 
in South-East Asia, the Eastern Mediterranean region, 
and the Western Pacific (0.6–3.2%). The most frequently 
reported macrovascular complications, after coronary 
artery disease and its components, were heart failure in 
Africa, the Americas, and Europe (0.9–10.7%), and stroke 
in South-East Asia, the Eastern Mediterranean region, 
and the Western Pacific (0.6–3.6%).
Multivariable analysis
Similar factors were found to have a statistically significant 
positive association with the prevalence of both micro-
vascular and macrovascular complications (Fig. 2). These 
included age (per 10-year increment; microvascular—
rate ratio: 1.14 [95% CI 1.09–1.19]; macrovascular—rate 
ratio: 1.41 [95% CI 1.34–1.48]), male sex (1.30 [1.20–1.42] 
and 1.29 [1.16–1.45]), having a low level of education 
(0–6 years in formal education relative to > 13 years; 1.17 
[1.05–1.30] and 1.19 [1.01–1.39]), duration of diabetes 
since diagnosis (per 1-year increment; 1.03 [1.02–1.04] 
and 1.02 [1.01–1.02]), and having a history of any hypogly-
cemic event (minor event in the previous month or major 
event in the previous year; 1.45 [1.25–1.69 and 1.24 [1.04–
1.48]). Increased mean baseline  HbA1c levels (per 1.0% 
increment) were positively associated with microvascular 
(rate ratio: 1.05 [95% CI 1.02–1.08]) but not macrovascular 
(rate ratio: 1.00 [95% CI 0.97–1.04]) complications. Being 
either a former or current smoker was positively associ-
ated with macrovascular complications (1.31 [1.20–1.40] 
and 1.24 [1.07–1.43]) relative to being a non-smoker.
Results from the sensitivity analyses including only 
patients with complete data (Additional file  1: Figure 
S1) and with additional variables for site specialty and 
patient-reported ethnicity (Additional file  1: Figure S2) 
were similar to those from the main analysis. Specialty 
and ethnicity were not associated with microvascular 
or macrovascular complications, with the exception of 
lower rates of macrovascular complications with self-
reported black versus Caucasian ethnicity and higher 
rates of macrovascular complications with self-reported 
East Asian versus Caucasian ethnicity.
Discussion
This large, prospective study of close to 16,000 patients 
with type 2 diabetes initiating second-line glucose-low-
ering therapy is being conducted in 38 countries across 
Percentages calculated for all patients with data available; unreported data are excluded
ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, ASA acetylsalicylic acid, BMI body mass index, DBP diastolic blood pressure, 
DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycated hemoglobin, IQR interquartile range, MET metformin, SBP systolic blood pressure, SD standard deviation, SU 
sulfonylurea, TC total cholesterol
a Minor hypoglycemic event in the previous month or major hypoglycemic event in the previous year
Table 1 (continued)
Total  
(N = 15,992)
Africa  
(n = 812)
Americas 
(n = 2002)
South-
East Asia 
(n = 3360)
Europe 
(n = 3479)
Eastern 
Mediterranean 
(n = 2182)
Western 
Pacific 
(n = 4157)
Comedication, n (%)
 ACEi or ARB 5862 (36.7) 315 (38.8) 827 (41.3) 990 (29.5) 1785 (51.3) 715 (32.8) 1230 (29.6)
 Diuretic 1867 (11.7) 223 (27.5) 250 (12.5) 203 (6.0) 780 (22.4) 197 (9.0) 214 (5.1)
 β‑blocker 2158 (13.5) 87 (10.7) 277 (13.8) 257 (7.6) 978 (28.1) 277 (12.7) 282 (6.8)
 Statin 6710 (42.0) 360 (44.3) 826 (41.3) 1497 (44.6) 1534 (44.1) 997 (45.7) 1496 (36.0)
 ASA 2562 (16.0) 214 (26.4) 374 (18.7) 278 (8.3) 776 (22.3) 485 (22.2) 435 (10.5)
First‑line therapy, n (%)
 MET mono‑
therapy
9076 (56.8) 679 (83.6) 1545 (77.2) 1505 (44.8) 2517 (72.4) 1063 (48.7) 1767 (42.5)
 SU monotherapy 1230 (7.7) 27 (3.3) 137 (6.8) 186 (5.5) 269 (7.7) 288 (13.2) 323 (7.8)
 DPP‑4i mono‑
therapy
1194 (7.5) 1 (0.1) 40 (2.0) 43 (1.3) 53 (1.5) 19 (0.9) 1038 (25.0)
 Other mono‑
therapy
631 (3.9) 2 (0.2) 17 (0.8) 36 (1.1) 59 (1.7) 13 (0.6) 504 (12.1)
 MET + SU 2300 (14.4) 73 (9.0) 135 (6.7) 1045 (31.1) 287 (8.3) 518 (23.8) 242 (5.8)
 MET + DPP‑4i 497 (3.1) 1 (0.1) 92 (4.6) 123 (3.7) 94 (2.7) 130 (6.0) 57 (1.4)
 MET + other 
(dual therapy)
266 (1.7) 18 (2.2) 3 (0.1) 61 (1.8) 56 (1.6) 16 (0.7) 112 (2.7)
 Other combina‑
tions
794 (5.0) 11 (1.4) 33 (1.6) 361 (10.7) 141 (4.1) 134 (6.1) 114 (2.7)
Page 7 of 13Kosiborod et al. Cardiovasc Diabetol          (2018) 17:150 
six continents. The burden of both microvascular and 
macrovascular complications at second-line therapy ini-
tiation, assessed using a standardized methodology, was 
found to be substantial and varied markedly between 
regions and countries. This study is one of the first to 
offer a truly global view of the prevalence of vascular 
complications among patients with type 2 diabetes who 
are at relatively early stages of their disease. DISCOVER 
also includes many lower- and upper-middle-income 
countries, for which no data on the prevalence of diabe-
tes complications were previously available.
When standardized for age and sex, the highest preva-
lence of microvascular and macrovascular complications 
was found in Europe, where patients also had the highest 
mean BMI and blood pressure, which are important car-
diovascular risk factors [26]. These findings could also be 
explained by rates of screening for complications being 
higher in Europe than in other regions, or by a greater 
proportion of patients seen in specialty settings. Across 
the European countries, Russia had the highest preva-
lence of microvascular and macrovascular complica-
tions. These observations are supported by Russian state 
diabetes registry data, which show a high prevalence of 
recorded vascular disease in patients with type 2 diabe-
tes, including 18.6% for diabetic neuropathy and 13.0% 
for diabetic retinopathy [27]. When excluding Russia 
from our analysis, the prevalence in Europe of macrovas-
cular complications, but not that of microvascular com-
plications, remained the highest across all regions.
Our multivariable analysis of factors potentially asso-
ciated with complication prevalence identified positive 
correlations between microvascular and macrovascular 
complications and age, male sex, low level of education, 
diabetes duration, and history of hypoglycemia. Other 
Table 2 Crude prevalence of  microvascular or  macrovascular diseases and  related procedures at  baseline, overall 
and according to region
Percentages calculated for all patients with data available; unreported data are excluded
CABG coronary artery bypass grafting, CAD coronary artery disease, CKD chronic kidney disease, PAD peripheral artery disease, PCI percutaneous coronary intervention
Total 
(N = 15,992)
Africa 
(n = 812)
Americas 
(n = 2002)
South-East 
Asia (n = 3360)
Europe 
(n = 3479)
Eastern 
Mediterranean 
(n = 2182)
Western 
Pacific 
(n = 4157)
Any microvascular 
disease, n (%)
3005 (18.8) 118 (14.5) 302 (15.1) 556 (16.5) 812 (23.5) 399 (18.3) 818 (19.7)
 CKD 794 (5.0) 20 (2.5) 90 (4.5) 23 (0.7) 257 (7.4) 31 (1.4) 373 (9.0)
 Albuminuria 605 (4.3) 21 (2.6) 40 (2.0) 188 (5.6) 195 (5.6) 91 (4.2) 70 (3.1)
 Retinopathy 624 (3.9) 22 (2.7) 68 (3.4) 30 (0.9) 198 (5.7) 69 (3.2) 237 (5.7)
 Retinal laser photoco‑
agulation
98 (0.6) 4 (0.5) 17 (0.8) 1 (0.0) 14 (0.4) 9 (0.4) 53 (1.3)
 Autonomic neuropa‑
thy
155 (1.0) 1 (0.1) 9 (0.4) 40 (1.2) 28 (0.8) 25 (1.1) 52 (1.3)
 Peripheral neuropathy 1237 (7.7) 47 (5.8) 114 (5.7) 324 (9.6) 324 (9.4) 181 (8.3) 247 (5.9)
 Erectile dysfunction 426 (2.7) 38 (4.7) 65 (3.2) 28 (0.8) 115 (3.3) 102 (4.7) 78 (1.9)
Any macrovascular 
disease, n (%)
2027 (12.7) 74 (9.1) 232 (11.6) 135 (4.0) 915 (26.7) 218 (10.0) 453 (10.9)
 Heart failure 527 (3.3) 7 (0.9) 54 (2.7) 18 (0.5) 368 (10.7) 23 (1.1) 57 (1.4)
 CAD 1310 (8.2) 59 (7.3) 151 (7.5) 91 (2.7) 622 (18.1) 172 (7.9) 215 (5.2)
  Angina 473 (3.0) 19 (2.3) 53 (2.6) 10 (0.3) 262 (7.6) 40 (1.8) 89 (2.1)
  Myocardial infarc‑
tion
445 (2.8) 39 (4.8) 80 (4.0) 18 (0.5) 228 (6.6) 31 (1.4) 49 (1.2)
  PCI 424 (2.7) 10 (1.2) 62 (3.1) 19 (0.6) 184 (5.4) 70 (3.2) 79 (1.9)
  CABG 140 (0.9) 10 (1.2) 17 (0.8) 13 (0.4) 71 (2.1) 15 (0.7) 14 (0.3)
Stroke 352 (2.2) 4 (0.5) 35 (1.7) 20 (0.6) 114 (3.3) 29 (1.3) 150 (3.6)
Transient ischemic 
attack
107 (0.7) 3 (0.4) 14 (0.7) 1 (0.0) 36 (1.0) 17 (0.8) 36 (0.9)
Carotid artery stent 16 (0.1) 0 (0.0) 1 (0.0) 0 (0.0) 7 (0.2) 4 (0.2) 4 (0.1)
Carotid endarterectomy 16 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 12 (0.3) 1 (0.0) 3 (0.1)
PAD 197 (1.2) 4 (0.5) 15 (0.7) 2 (0.1) 108 (3.1) 10 (0.5) 58 (1.4)
  Diabetic foot 87 (0.5) 4 (0.5) 20 (1.0) 15 (0.4) 32 (0.9) 7 (0.3) 9 (0.2)
  Amputation 32 (0.2) 6 (0.7) 12 (0.6) 1 (0.0) 9 (0.3) 3 (0.1) 1 (0.0)
Defibrillator use 8 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 7 (0.2) 0 (0.0) 1 (0.0)
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research has shown that greater and more prolonged 
exposure to hyperglycemia, as would occur in patients 
with a long duration of uncontrolled type 2 diabetes, 
increases the risk of both microvascular and macrovas-
cular complications [28]. Of note, a significant associa-
tion was observed in the current analysis between  HbA1c 
level and microvascular, but not macrovascular, com-
plications. This is consistent with previous findings that 
intensive glycemic control decreases the incidence of 
microvascular complications, with much less certainty in 
terms of its effects on macrovascular events [7–12, 29].
Large, international, observational studies that have 
reported the prevalence of vascular complications in 
patients with type 2 diabetes are rare. The  A1chieve study 
was a global, prospective, observational study of more 
than 66,000 patients with type 2 diabetes from 28 coun-
tries in Asia, Africa, Europe, and South America, and 
reported a prevalence of microvascular complications at 
baseline of 53.5%, and of macrovascular complications of 
27.2% [21]. However, the patients included in that study 
were initiating insulin analogs, typically administered 
after failure to achieve target  HbA1c levels with other 
a
b
Region
Africa
Americas
Asia
Pacific
Country
Overall
Algeria
Overall
Brazil
Overall
Overall
Overall
Overall
n
299
455
92
454
588
225
95
258
Micro-
vascular
%
Macro-
vascular
%
Fig. 1 Age‑ and sex‑standardized prevalence of a microvascular and b macrovascular complications, according to region and country. Percentages 
calculated for all patients with data available; unreported data are excluded. UAE United Arab Emirates
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glucose-lowering drugs. Consequently, the patients in 
 A1chieve had a much longer duration of diabetes than 
those in DISCOVER (mean 8.0 vs 5.6 years) and a higher 
mean baseline  HbA1c level (9.5% vs 8.4%).
The IMPROVE study, conducted in eight countries and 
involving more than 50,000 patients receiving insulin ther-
apy, also reported a high prevalence of both microvascu-
lar and macrovascular complications (45.0% and 28.0%, 
respectively) [30]. Again, the mean duration of diabetes 
(6.9  years) and mean  HbA1c levels (9.4%) were higher in 
IMPROVE than in the DISCOVER study. The Interna-
tional Diabetes Management Practice Study (IDMPS) was 
conducted in 18 developing countries across Asia, East-
ern Europe, and Latin America. The prevalence estimates 
reported for microvascular and macrovascular complica-
tions were again high at 55.3% and 26.1%, respectively [31]. 
In this survey of a general population of patients with type 
2 diabetes, the mean diabetes duration was 8.4 years, and 
31% of patients were treated with insulin, either on its own 
or in combination with oral agents.
The differences in patient characteristics between 
 A1chieve, IMPROVE, IDMPS, and DISCOVER are likely 
to explain the differences in the observed rates of vascular 
complications. All three of the previous studies included 
Age (per 10-year increment) 
Male (versus female) 
Time in formal education (versus > 13 years) 
0–6 years 
7–13 years 
Smoking status (versus non-smoker) 
Ex-smoker 
Current smoker 
BMI (per 5 kg/m2 increment)
HbA1c (per 1% increment)
Diabetes duration (per 1-year increment) 
History of hypoglycemiab (yes versus no)
RR (95% CI)a
0.65 1.000.80 1.25 1.56
0.25 1.000.50 2.00 4.00
a
Increased likelihood of
complications 
Decreased likelihood of
complications 
Increased likelihood of
complications 
Decreased likelihood of
complications 
Age (per 10-year increment) 
Male (versus female) 
Time in formal education (versus > 13 years) 
0–6 years 
7–13 years 
Smoking status (versus non-smoker) 
Ex-smoker 
Current smoker 
BMI (per 5 kg/m2 increment)
HbA1c (per 1% increment)
Diabetes duration (per 1-year increment) 
History of hypoglycemiab (yes versus no)
1.14 (1.09–1.19)
1.30 (1.20–1.42)
1.17 (1.05–1.30)
1.03 (0.95–1.12)
1.14 (1.00–1.30)
1.11 (0.97–1.26)
1.03 (0.99–1.06)
1.05 (1.02–1.08)
1.03 (1.02–1.04)
1.45 (1.25–1.69)
1.41 (1.34–1.48)
1.29 (1.16–1.45)
1.19 (1.01–1.39)
1.13 (1.02–1.25)
1.31 (1.20–1.44)
1.24 (1.07–1.43)
1.00 (0.96–1.04)
1.00 (0.97–1.04)
1.02 (1.01–1.02)
1.24 (1.04–1.48)
b RR (95% CI)a
Fig. 2 Multivariable analysis of factors associated with a microvascular and b macrovascular complications. aRRs adjusted for all variables in the 
figure with the addition of SBP, total cholesterol levels and comedication use, using a modified Poisson model with cluster‑based sandwich variance 
estimator as described in “Methods”. RRs for the associations between complication prevalence and SBP, total cholesterol levels, and comedication 
use are not reported due to reverse‑causality. bMinor hypoglycemic event in the previous month or major hypoglycemic event in the previous year. 
BMI body mass index, CI confidence interval, HbA1c glycated hemoglobin, RR rate ratio
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patients with longer-term disease than in DISCOVER. 
Our study is therefore the first global observational study 
of its kind, evaluating a population of patients with a 
much shorter disease duration.
Our findings highlight a key opportunity for improved 
monitoring of complications, and the importance of early 
and aggressive risk factor modification. This is in line with 
current practice guidelines; for example, the European 
Society of Cardiology guidelines for cardiovascular disease 
prevention consider patients with diabetes to be at very 
high cardiovascular risk, regardless of other risk factors, 
and therefore recommend statin treatment in addition to 
intensive blood pressure management for all patients [32]. 
The American Heart Association and American Diabetes 
Association similarly recommend intensive management 
of cardiovascular risk factors in patients with diabetes 
[33]. As outlined in the American Diabetes Association/
European Association for the Study of Diabetes joint posi-
tion statement, it is also important to consider classes of 
glucose-lowering medications with positive impacts on 
cardiovascular risk factors, especially in patients with 
established cardiovascular disease [34]. In a recent, large 
cohort study, patients with type 2 diabetes who had levels 
of  HbA1c, cholesterol, serum albumin and blood pressure 
all within target ranges, and who did not smoke, were at 
similar risk of myocardial infarction or stroke as age-, sex- 
and country-matched controls [35]. Risk scores can help 
clinicians identify patients with type 2 diabetes who are at 
low or high risk of vascular disease [36, 37].
The main strengths of the DISCOVER study include its 
prospective design, the large number of patients enrolled, 
and the participation of lower- and upper-middle-income 
countries where patients have rarely, or never, been stud-
ied previously. The use of a standardized electronic case 
report form is another key strength of the study, allowing 
valid comparisons of results within and across countries 
and regions worldwide. In addition, sites were selected in 
a way intended to ensure that the enrolled patient popu-
lation is as diverse and representative as possible of the 
general population of patients with type 2 diabetes.
Our findings should, nevertheless, be interpreted in the 
context of several potential limitations. The ascertain-
ment and diagnosis of diabetes-related vascular complica-
tions were based on the judgment of individual physicians, 
and we could not determine whether the complications 
occurred before or after the diagnosis of type 2 diabetes. 
In some countries, rural sites do not have any established 
infrastructure for data collection, and primary care prac-
titioners may be insufficiently trained, or not permitted, 
to conduct observational research. In these countries, 
where rural sites and primary care settings are necessarily 
under-represented, the quality of healthcare is likely to be 
overestimated.
The observational nature of the DISCOVER study means 
that the study protocol does not mandate screening for 
complications, and that the presence and severity of com-
plications are not adjudicated. The reported prevalence 
estimates may therefore be underestimates, because physi-
cians may not be aware of complications in some patients. 
In many lower- and upper-middle-income countries par-
ticipating in DISCOVER, fundus cameras used for retin-
opathy screening may be inaccessible to many patients, 
particularly in rural areas [38].
In the present analysis, we considered erectile dysfunc-
tion to be a microvascular complication, and diabetic foot 
to be a macrovascular complication. However, no assess-
ment of the underlying pathophysiology of these condi-
tions in individual patients was made. Finally, imputation 
was required during the multivariable analysis to account 
for some unreported data, in particular for  HbA1c and total 
cholesterol. This is consistent with the noninterventional 
nature of the DISCOVER study, whereby laboratory val-
ues and other clinical variables are measured according to 
standard clinical practice at each site. In several countries, 
measurement of biomarkers including  HbA1c and total 
cholesterol may not be covered by health insurance, and 
may therefore not be routinely measured for all patients.
Conclusions
The prevalence of microvascular and macrovascular 
complications in patients with type 2 diabetes at second-
line therapy initiation, assessed using a standardized 
methodology, varied markedly across regions and coun-
tries worldwide, and highlighted significant opportunities 
for better risk factor modification and prevention. Across 
all regions, Europe had the highest prevalence of both 
microvascular complications and macrovascular compli-
cations, the former being driven by high rates in Russia. 
Over the coming years, the DISCOVER study program 
will add to our understanding by providing follow-up 
longitudinal data on the incidence of complications fol-
lowing initiation of second- and later-line therapies.
Additional file
Additional file 1: Table S1. Inclusion and exclusion criteria. DDP‑4 
dipeptidyl peptidase‑4. a≥ 20 years in Japan. bIn Japan, only patients using 
an oral monotherapy as first‑line treatment were included. Table S2. 
Comparisons between patients for whom either  HbA1c or total cholesterol 
data are unreported, and those with complete  HbA1c and total cholesterol 
data. ACEi angiotensin‑converting‑enzyme inhibitor, ARB angiotensin 
receptor blocker, ASA acetylsalicylic acid, BMI body mass index, HbA1c 
glycated hemoglobin, SBP systolic blood pressure, SD standard deviation, 
TC total cholesterol. aPatients with reported data for all variables included 
in the hierarchical logistic model. bP values calculated for continuous 
variables using Student’s t‑test, and for categorical variables using the 
χ2 or Fisher’s exact test, as appropriate. cMinor hypoglycemic event in 
the previous month or major hypoglycemic event in the previous year. 
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Table S3. Number and proportion of patients with microvascular and 
macrovascular complications according to country (unadjusted). Percent‑
ages were calculated for all patients with data available; unreported data 
were excluded. UAE United Arab Emirates. Figure S1. Sensitivity analysis 
including only patients with complete data to assess factors associated 
with (A) microvascular and (B) macrovascular complications. aRRs adjusted 
for all variables in the figure with the addition of SBP, total, cholesterol 
levels and comedication use, using a modified Poisson model with cluster‑
based sandwich variance estimator as described in “Methods”. RRs for the 
associations between complication prevalence and SBP, total cholesterol 
levels, and comedication use are not reported due to reverse‑causality. 
bMinor hypoglycemic event in the previous month or major hypogly‑
cemic event in the previous year. BMI body mass index, CI confidence 
interval, HbA1c glycated hemoglobin, RR rate ratio. Figure S2. Sensitivity 
analysis with additional variables for site specialty and patient‑reported 
ethnicity to assess factors associated with (A) microvascular and (B) mac‑
rovascular complications. aRRs adjusted for all variables in the figure with 
the addition of SBP, total, cholesterol levels and comedication use, using a 
modified Poisson model with cluster‑based sandwich variance estimator 
as described in “Methods”. RRs for the associations between complication 
prevalence and SBP, total cholesterol levels, and comedication use are 
not reported due to reverse‑causality. bMinor hypoglycemic event in the 
previous month or major hypoglycemic event in the previous year. BMI 
body mass index, CI confidence interval, HbA1c glycated hemoglobin, RR 
rate ratio.
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